Vascular endothelial growth factor in patients with hepatocellular carcinoma: Effects of transcatheter arterial embolization

被引:0
作者
Yoshiyama, Y [1 ]
Mitsuyama, K [1 ]
Ono, N [1 ]
Matsuo, K [1 ]
Tanikawa, K [1 ]
机构
[1] TOAGOSEI CHEM IND,TSUKUBA RES LAB,BIOSCI RES DEPT,IBARAKI,OSAKA,JAPAN
关键词
vascular endothelial growth factor; hepatocellular carcinoma; liver cirrhosis; transcatheter arterial embolization;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The main aims of this study were to analyze the significance of serum vascular endothelial growth factor (VEGF) levels in the development of hepatocellular carcinoma, and the effect of transcatheter arterial embolization treatment on the production of VEGF. Serum VEGF levels in hepatocellular carcinoma were significantly higher than in liver cirrhosis (P<0.01) but not significantly different from normal controls. Serum VEGF levels in cirrhosis decreased gradually as the Pugh-Child grade increased in severity. In hepatocellular carcinoma serum VEGF levels were not related to the tumor stage or serum levels of the tumor markers, cr-fetoprotein and des-gamma-carboxy prothrombin. In 18 patients who underwent transcatheter arterial embolization, serum VEGF increased gradually and reached a peak at day 7, although serum interleukin-6 and hepatocyte growth factor levels peaked at days 1-3 and then decreased. VEGF levels were elevated significantly in patients who did not respond to transcatheter arterial embolization treatment as compared to those who responded to this treatment (P<0.05). Serum VEGF levels may be useful in the assessment of hepatocellular carcinoma patients and may indicate responsiveness to transcatheter arterial embolization.
引用
收藏
页码:577 / 582
页数:6
相关论文
共 39 条
[1]   BLOOD-SUPPLY OF EARLY HEPATOCELLULAR-CARCINOMA [J].
BHATTACHARYA, S ;
DAVIDSON, B ;
DHILLON, AP .
SEMINARS IN LIVER DISEASE, 1995, 15 (04) :390-401
[2]   TRANSCATHETER MANAGEMENT OF PRIMARY-CARCINOMA OF THE LIVER [J].
CHARNSANGAVEJ, C ;
CHUANG, VP ;
WALLACE, S ;
SOO, CS ;
BOWERS, T .
RADIOLOGY, 1983, 147 (01) :51-55
[3]   THERAPEUTIC EFFECT OF TRANSCATHETER OILY CHEMOEMBOLIZATION THERAPY FOR ENCAPSULATED NODULAR HEPATOCELLULAR-CARCINOMA - CT AND PATHOLOGICAL FINDINGS [J].
CHOI, BI ;
KIM, HC ;
HAN, JK ;
PARK, JH ;
KIM, YI ;
KIM, ST ;
LEE, HS ;
KIM, CY ;
HAN, MC .
RADIOLOGY, 1992, 182 (03) :709-713
[4]   OVEREXPRESSION OF VASCULAR-PERMEABILITY FACTOR VASCULAR ENDOTHELIAL GROWTH-FACTOR AND ITS RECEPTORS IN PSORIASIS [J].
DETMAR, M ;
BROWN, LF ;
CLAFFEY, KP ;
YEE, KT ;
KOCHER, O ;
JACKMAN, RW ;
BERSE, B ;
DVORAK, HF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (03) :1141-1146
[5]   PITUITARY FOLLICULAR CELLS SECRETE A NOVEL HEPARIN-BINDING GROWTH-FACTOR SPECIFIC FOR VASCULAR ENDOTHELIAL-CELLS [J].
FERRARA, N ;
HENZEL, WJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 161 (02) :851-858
[6]   ANGIOGENIC FACTORS [J].
FOLKMAN, J ;
KLAGSBRUN, M .
SCIENCE, 1987, 235 (4787) :442-447
[7]   STRUCTURAL CHARACTERIZATION AND BIOLOGICAL FUNCTIONS OF FIBROBLAST GROWTH-FACTOR [J].
GOSPODAROWICZ, D ;
FERRARA, N ;
SCHWEIGERER, L ;
NEUFELD, G .
ENDOCRINE REVIEWS, 1987, 8 (02) :95-114
[8]   SENSITIVE CHEMILUMINESCENCE ENZYME-IMMUNOASSAY FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR VASCULAR-PERMEABILITY FACTOR IN HUMAN SERUM [J].
HANATANI, M ;
TANAKA, Y ;
KONDO, S ;
OHMORI, I ;
SUZUKI, H .
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 1995, 59 (10) :1958-1959
[9]  
Hermanek P., 1987, TNM Classification of Malignant Tumors, V4th edn
[10]  
HIRAI K, 1989, CANC CHEMOTHER PHA S, V23, P37